Purpose: To evaluate perioperative outcomes and the learning curve of robotic pancreatoduodenectomy (RPD) in a high-volume pancreatic surgery program. Methodology: We retrospectively reviewed 135 consecutive RPDs performed between 2018 and 2025. A standardized left-sided approach, previously reported by our group, was adopted (Nakata et al., Surg Endosc 2023). Pancreatic reconstruction was tailored to patient risk; pancreaticogastrostomy was performed in 119 cases (88.1%). Outcomes were graded by Clavien–Dindo and ISGPS definitions. Operative-time CUSUM analysis assessed the learning curve. Results: Indications included pancreatic ductal adenocarcinoma (PDAC) in 39 cases (28.9%). Median operative time was 612 min (IQR 527–739) and median blood loss was 230 g (IQR 75–410). Conversion occurred in 3 cases (2.2%) and transfusion in 3 (2.2%). Clinically relevant POPF (grade B/C) occurred in 44 cases (32.6%); all were grade B with no grade C. DGE (grade B/C) occurred in 8 cases (5.9%). PPH (grade B/C) occurred in 4 cases (3.0%); all were grade B with no grade C. Major morbidity (Clavien–Dindo ≥III) occurred in 31 cases (23.0%). Median length of stay was 26 days with no in-hospital mortality. Among PDAC patients undergoing RPD, R0 resection was achieved in 37/39 (94.9%). With evolving indications including PDAC, operative-time CUSUM in the non-PDAC cohort identified a transition point at case 29. Conclusion: RPD was implemented with low conversion and transfusion rates, no in-hospital mortality, and no grade C fistula or hemorrhage. Standardized strategies may support safe and reproducible adoption of RPD.